Bank of New York Mellon Corp Has $4.17 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)

Bank of New York Mellon Corp cut its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 13.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 290,031 shares of the company's stock after selling 45,337 shares during the period. Bank of New York Mellon Corp owned about 0.24% of 10x Genomics worth $4,165,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Assenagon Asset Management S.A. bought a new position in 10x Genomics in the 4th quarter valued at $26,308,000. Point72 Asset Management L.P. bought a new position in 10x Genomics in the 3rd quarter valued at $27,778,000. FMR LLC boosted its position in 10x Genomics by 2.7% in the 3rd quarter. FMR LLC now owns 13,367,979 shares of the company's stock valued at $301,849,000 after buying an additional 357,470 shares during the last quarter. JPMorgan Chase & Co. boosted its position in 10x Genomics by 355.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock valued at $8,027,000 after buying an additional 277,355 shares during the last quarter. Finally, Algert Global LLC boosted its position in 10x Genomics by 214.5% in the 3rd quarter. Algert Global LLC now owns 370,958 shares of the company's stock valued at $8,376,000 after buying an additional 252,994 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Barclays cut their price target on 10x Genomics from $19.00 to $18.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research note on Friday, March 7th. UBS Group cut their price target on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Stifel Nicolaus cut their price target on 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Finally, Canaccord Genuity Group dropped their price objective on 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $20.21.

Remove Ads

10x Genomics Stock Up 4.4 %

Shares of NASDAQ:TXG traded up $0.44 during mid-day trading on Friday, reaching $10.39. 3,433,644 shares of the stock were exchanged, compared to its average volume of 2,002,483. The company has a market cap of $1.27 billion, a P/E ratio of -6.84 and a beta of 1.93. 10x Genomics, Inc. has a one year low of $9.27 and a one year high of $38.49. The stock's 50 day simple moving average is $12.68 and its 200-day simple moving average is $15.58.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Insider Activity

In other 10x Genomics news, Director Alan Mateo acquired 40,000 shares of the business's stock in a transaction dated Friday, February 21st. The stock was bought at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the transaction, the director now directly owns 61,691 shares in the company, valued at approximately $687,237.74. This represents a 184.41 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the sale, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at approximately $9,735,865.74. The trade was a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.03% of the company's stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.